中晚期原发性肝癌内科治疗的研究进展(4)
[10]Jonker DJ，Rosen LS，Sawyer MB，et al.A phase Ⅰ study to determine the safety，pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor，brivanib，in patients with advanced or metastatic solid tumors[J].Ann Oncol，2011，22(6)：1413-1419.[11]Finn RS，Kang YK，Mulcahy M，et al.Phase Ⅱ，open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma[J].Clin Cancer Res ......
您现在查看是摘要页，全文长 2723 字符。